Biotech - Drug Development
Biotechnology companies developing novel therapeutics across disease areas (excluding oncology-focused)
Rare Disease Therapeutics152
Neuroscience & CNS90
Immunology & Autoimmune80
Metabolic & Cardiometabolic42
Infectious Disease & Vaccines51
Clinical-Stage Platforms149
| Ticker | Company | Sub-Theme | Mkt Cap▼ | Price | Chg% | Volume |
|---|---|---|---|---|---|---|
 LLY | Eli Lilly & Co. | Metabolic & Cardiometabolic | $1.0t | $1169.34 | +3.4% | 1.5M |
 JNJ | Johnson & Johnson | Immunology & Autoimmune | $0.5t | $232.12 | -0.3% | 1.5M |
 ABBV | ABBVIE INC. | Immunology & Autoimmune | $384.7b | $224.26 | -1.3% | 1.2M |
 MRK | Merck & Co., Inc. | Infectious Disease & Vaccines | $293.2b | $120.91 | +0.1% | 2.3M |
 AZN | AstraZeneca PLC | Metabolic & Cardiometabolic | $287.9b | $183.90 | -1.1% | 630.7K |
 TMO | Thermo Fisher Scientific, Inc. | Clinical-Stage Platforms | $183.0b | $474.47 | +0.4% | 345.4K |
 AMGN | Amgen Inc | Immunology & AutoimmuneRare Disease Therapeutics | $181.8b | $346.84 | -0.8% | 440.9K |
 GILD | Gilead Sciences Inc | Infectious Disease & Vaccines | $166.9b | $128.72 | -0.3% | 1.4M |
 PFE | Pfizer Inc. | Infectious Disease & Vaccines | $149.2b | $25.96 | -0.3% | 10.0M |
 BMY | Bristol-Myers Squibb Co. | Immunology & Autoimmune | $116.8b | $56.84 | -0.7% | 2.5M |
 VRTX | Vertex Pharmaceuticals Inc | Rare Disease Therapeutics | $113.6b | $447.55 | +0.2% | 219.4K |
 REGN | Regeneron Pharmaceuticals Inc | Immunology & Autoimmune | $64.5b | $623.11 | -1.9% | 125.9K |
 ALNY | Alnylam Pharmaceuticals, Inc. | Rare Disease Therapeutics | $40.3b | $288.42 | -4.8% | 479.1K |
 A | Agilent Technologies Inc. | Clinical-Stage Platforms | $38.2b | $135.37 | -0.0% | 228.8K |
 WAT | Waters Corp | Clinical-Stage Platforms | $37.7b | $368.49 | +0.9% | 114.5K |
 IQV | IQVIA Holdings Inc. | Clinical-Stage Platforms | $30.4b | $184.25 | +0.4% | 148.1K |
 BIIB | Biogen Inc. Common Stock | Neuroscience & CNS | $28.9b | $195.58 | +0.1% | 241.7K |
 RPRX | Royalty Pharma plc Class A Ordinary Shares | Clinical-Stage Platforms | $24.7b | $55.84 | -0.1% | 990.5K |
 UTHR | United Therapeutics Corp | Rare Disease Therapeutics | $23.6b | $552.23 | +0.4% | 85.7K |
 INSM | Insmed, Inc. | Rare Disease Therapeutics | $23.2b | $96.09 | +2.0% | 1.3M |
 WST | West Pharmaceutical Services, Inc. | Clinical-Stage Platforms | $22.8b | $318.34 | +1.2% | 67.2K |
 ROIV | Roivant Sciences Ltd. Common Shares | Immunology & Autoimmune | $21.6b | $28.58 | -0.0% | 773.6K |
 INCY | Incyte Genomics Inc | Rare Disease Therapeutics | $19.3b | $101.58 | -0.8% | 767.3K |
 MRNA | Moderna, Inc. Common Stock | Infectious Disease & Vaccines | $18.7b | $48.44 | +2.1% | 1.0M |
 NBIX | Neurocrine Biosciences Inc | Neuroscience & CNS | $15.9b | $162.99 | -0.5% | 136.7K |
 JAZZ | Jazz Pharmaceuticals, Inc. | Neuroscience & CNS | $14.8b | $237.04 | -0.6% | 122.8K |
 ASND | Ascendis Pharma A/S Ordinary Share | Clinical-Stage Platforms | $13.8b | $205.06 | -2.6% | 80.3K |
 SMMT | Summit Therapeutics Inc. Common Stock | Infectious Disease & Vaccines | $13.6b | $14.63 | -1.0% | 989.9K |
 BBIO | BridgeBio Pharma, Inc. Common Stock | Rare Disease Therapeutics | $13.0b | $67.85 | +0.4% | 248.7K |
 MEDP | Medpace Holdings, Inc. Common Stock | Clinical-Stage Platforms | $12.8b | $459.84 | +1.2% | 31.2K |
 IONS | Ionis Pharmaceuticals, Inc. Common Stock | Rare Disease Therapeutics | $12.6b | $74.09 | -0.5% | 321.1K |
 AXSM | Axsome Therapeutics, Inc | Neuroscience & CNS | $12.1b | $237.66 | +2.3% | 142.0K |
 RGC | Regencell Bioscience Holdings Limited Ordinary Shares | Neuroscience & CNS | $11.8b | $21.10 | +5.6% | 32.3K |
 RVTY | Revvity, Inc. | Clinical-Stage Platforms | $11.7b | $102.02 | +3.7% | 309.6K |
 MDGL | Madrigal Pharmaceuticals, Inc. Common Stock | Metabolic & Cardiometabolic | $11.5b | $477.95 | -1.9% | 46.5K |
 BMRN | BioMarin Pharmaceuticals Inc | Rare Disease Therapeutics | $11.1b | $56.49 | -0.5% | 267.4K |
 ARWR | Arrowhead Research Corporation | Rare Disease Therapeutics | $11.0b | $73.44 | +0.5% | 196.5K |
 CYTK | Cytokinetics Inc. | Rare Disease TherapeuticsNeuroscience & CNS | $10.4b | $69.33 | -3.0% | 399.5K |
 ICLR | Icon Plc | Clinical-Stage Platforms | $10.4b | $151.28 | +1.2% | 163.6K |
 PRAX | Praxis Precision Medicines, Inc. Common Stock | Neuroscience & CNS | $9.8b | $250.99 | -1.2% | 123.3K |
 KRYS | Krystal Biotech, Inc. Common Stock | Rare Disease Therapeutics | $9.1b | $304.06 | +1.0% | 44.0K |
 BRKR | Bruker Corporation | Clinical-Stage Platforms | $9.0b | $57.69 | +2.3% | 528.6K |
 CRL | Charles River Laboratories International, Inc. | Clinical-Stage Platforms | $8.7b | $185.23 | +2.1% | 106.0K |
 BIO.B | Bio-Rad Laboratories, Inc. Class B | Clinical-Stage Platforms | $8.1b | $306.58 | +0.8% | 2 |
 TECH | Bio-Techne Corp. | Clinical-Stage Platforms | $8.1b | $53.34 | +2.6% | 848.0K |
 HALO | Halozyme Therapeutics, Inc. | Clinical-Stage Platforms | $7.9b | $71.27 | -0.4% | 381.4K |
 IBRX | ImmunityBio, Inc. Common Stock | Immunology & Autoimmune | $7.9b | $7.06 | +2.1% | 3.9M |
 QGEN | QIAGEN N.V. | Clinical-Stage Platforms | $7.5b | $36.67 | -0.0% | 347.5K |
 CORT | Corcept Therapeutics Inc. | Rare Disease Therapeutics | $7.5b | $74.78 | +3.0% | 157.0K |
 PCVX | Vaxcyte, Inc. Common Stock | Infectious Disease & Vaccines | $7.4b | $46.29 | -2.3% | 156.7K |